A recent study involving 2,401 women with breast cancer revealed that 4.8% harbored pathogenic or likely pathogenic variants of BRCA1 or BRCA2. Conducted across two City of Hope sites in Southern California between July 2020 and October 2023, patients diagnosed with various stages of breast cancer underwent comprehensive testing that included a 155-gene panel. The study highlighted significant variations in variant prevalence among different racial and ethnic groups, underscoring the importance of genetic testing in guiding treatment and advocating for universal testing, especially in minority groups.

Source: JAMA Network Open